Investigational drug · Phase 3
INCB161734
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "INCB161734"
First trial start
2026
Apr 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INCB161734", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INCB161734" as an intervention, largest first.
Incyte CorporationIncyte (INCY)
NCT06179160 · 710 participants (planned) · Start Jan 4, 2024 · Primary completion Jan 1, 2027
Drug: INCB161734; Cetuximab and 6 more · For: Solid Tumors
Sites: Phoenix, Arizona; Palo Alto, California; Santa Monica, California · 34 sites in all
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07522073 · 588 participants (planned) · Start Apr 9, 2026 · Primary completion Sep 15, 2028
Drug: INCB161734; Placebo and 1 more · For: Solid Tumors
Sites: Birmingham, Alabama; Anchorage, Alaska; Chandler, Arizona · 230 sites in all
Incyte CorporationIncyte (INCY)
NCT07018635 · 63 participants · Start Jul 16, 2025 · Primary completion Sep 29, 2025
Drug: INCB161734; Itraconazole and 3 more · For: Healthy Participants
Sites: Madison, Wisconsin
Incyte CorporationIncyte (INCY)
NCT07853040 · 24 participants (planned) · Start Oct 27, 2026 · Primary completion Mar 31, 2027
Drug: INCB161734 · For: Hepatic Insufficiency; Liver Diseases
Sites: Chandler, Arizona; Orlando, Florida; San Antonio, Texas
- A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on HemodialysisNot yet recruiting
Incyte CorporationIncyte (INCY)
NCT07854249 · 24 participants (planned) · Start Oct 26, 2026 · Primary completion Mar 30, 2027
Drug: INCB161734 · For: Renal Insufficiency; Kidney Diseases
Incyte CorporationIncyte (INCY)
NCT07814404 · 10 participants · Start Sep 18, 2026 · Primary completion Oct 15, 2026
Drug: INCB161734 · For: Healthy Participants
Sites: Lincoln, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant.
Sokolsky A, Yin H, Ye Q, et al. · J Med Chem 2026
- KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
Abdelhakeem A, Ganatra N, Gul K, et al. · J Hematol Oncol 2026
- The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?
Dempke WCM, Sippel C, Fenchel K, et al. · Future Oncol 2026
- Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.
Jeon E, Song J, Sim T · Future Med Chem 2026
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.